Immune checkpoint inhibitors (ICIs) are a novel class of drugs that target the programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway and have been approved as first-line therapy for serious cancers (1). This evidence concerns the gene PDCD1 and cancer.